Request for Proposals (RFP)
Applications Due: 02/18/2022
Specific Area of Interest: Pfizer and Lilly aim to support educational activities related to the BRAF V600-mutant mCRC disease state, tailored to community practices.
Projects that will be considered for Pfizer and Lilly support will focus on educating those involved in both the diagnosis and treatment of patients with mCRC, specifically with regard to:
- Incidence and prognosis of BRAF V600-mutant mCRC and its relevance to other clinical features, e.g., histology, sidedness
- The need for biomarker testing in metastatic CRC
- Treatment selection and sequencing for this patient population
- Safe and appropriate use of therapy, including dosing and management of side effects